Daclizumab (Zenapax) shows promise in MS
Posted: Mon Oct 24, 2011 1:13 am
Treatment with daclizumab (Zenapax), an investigational monoclonal antibody drug, cut annualized relapse rates in half among patients with early relapsing-remitting multiple sclerosis (MS) in a placebo-controlled trial, a researcher said here.
Annualized relapse rates averaged 0.21 and 0.23 with two different dosage levels of daclizumab, compared with 0.46 for patients put on placebo in the one-year, 600-patient trial known as SELECT (both P<0.001), reported Gavin Giovannoni, MD, of Queen Mary University in London.
The drug also showed significant efficacy in a host of secondary outcomes, including physical function, disability progression, and MRI lesion burden, he said at the joint meeting of the European and American Committees for Treatment and Research in Multiple Sclerosis.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1502